Protein (1)
Launched (1)
Human (1)
His Tag & Avi Tag (1)
Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HLS-H82E4 | HEK293 | Biotinylated Human HLA-A*02:01&B2M&KRAS (KLVVVGAGGV) Complex Protein (Monomer, MALS verified) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| IMVT-1402 | HL-161 ANS; IMVT-1402 | Phase 2 Clinical | Immunovant Sciences Gmbh, HanAll Biopharma Co Ltd | Autoimmune Diseases; Graves Disease | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Efgartigimod alfa | ARGX-113; EFG PH20; EFG PH20 SC; PH20 SC; ARGX-113-2308 | Approved | Argenx Se | VYVGART HYTRULO, VYVDURA, VYVGART, 卫伟迦 | United States | Myasthenia Gravis | Argenx BV | 2021-12-17 | Graves Ophthalmopathy; Tachycardia; Pemphigus; Thrombocytopenia; Guillain-Barre Syndrome; Eye Diseases; Nephrotic Syndrome; Muscular Diseases; Pemphigoid, Bullous; Optic Neuritis; Glomerulonephritis, Membranous; Rejection of organ transplantation; Purpura, Thrombocytopenic, Idiopathic; Lupus Nephritis; Scleroderma, Systemic; Stiff-Person Syndrome; Sjogren's Syndrome; Postural Orthostatic Tachycardia Syndrome; Polyneuropathies; Myositis; Nephrosis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Myasthenia Gravis | Details |
| Rozanolixizumab | UCB-7665 | Approved | Ucb Sa | RYSTIGGO | United States | Myasthenia Gravis | Ucb Inc | 2023-06-27 | Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Encephalitis; Fibromyalgia | Details |
| Efgartigimod alfa/Hyaluronidase | Approved | Argenx BV | VYVDURA, VYVGART HYTRULO | United States | Myasthenia Gravis | Argenx BV | 2023-06-20 | Myasthenia Gravis | Details |




